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Abstract
Introduction Mechanical ventilation with even moderate-sized
tidal volumes synergistically increases lung injury in sepsis and
has been associated with proinflammatory low-molecular-weight
hyaluronan production. High-molecular-weight hyaluronan
(HMW HA), in contrast, has been found to be anti-inflammatory.
We hypothesized that HMW HA would inhibit lung injury
associated with sepsis and mechanical ventilation.
Methods Sprague–Dawley rats were randomly divided into four
groups: nonventilated control rats; mechanical ventilation plus
lipopolysaccharide (LPS) infusion as a model of sepsis;
mechanical ventilation plus LPS with HMW HA (1,600 kDa)
pretreatment; and mechanical ventilation plus LPS with low-
molecular-weight hyaluronan (35 kDa) pretreatment. Rats were
mechanically ventilated with low (7 ml/kg) tidal volumes. LPS (1
or 3 mg/kg) or normal saline was infused 1 hour prior to
mechanical ventilation. Animals received HMW HA or low-
molecular-weight hyaluronan via the intraperitoneal route 18
hours prior to the study or received HMW HA (0.025%, 0.05%
or 0.1%) intravenously 1 hour after injection of LPS. After 4
hours of ventilation, animals were sacrificed and the lung
neutrophil and monocyte infiltration, the cytokine production,
and the lung pathology score were measured.
Results LPS induced lung neutrophil infiltration, macrophage
inflammatory protein-2 and TNFα mRNA and protein, which
were decreased in the presence of both 1,600 kDa and 35 kDa
hyaluronan pretreatment. Only 1,600 kDa hyaluronan
completely blocked both monocyte and neutrophil infiltration
and decreased the lung injury. When infused intravenously 1
hour after LPS, 1,600 kDa hyaluronan inhibited lung neutrophil
infiltration, macrophage inflammatory protein-2 mRNA
expression and lung injury in a dose-dependent manner. The
beneficial effects of hyaluronan were partially dependent on the
positive charge of the compound.
Conclusions HMW HA may prove to be an effective treatment
strategy for sepsis-induced lung injury with mechanical
ventilation.
BAL: bronchoalveolar lavage; CMC: sodium carboxymethyl cellulose; ELISA: enzyme-linked immunosorbent assay; HA: hyaluronan; HAS: hyaluronan 
synthase; HMW HA: high-molecular-weight hyaluronan; IFN: interferon; IL: interleukin; JNK: c-Jun NH2-terminal kinase; LMW HA: low-molecular-
weight hyaluronan; LPS: lipopolysaccharide; MIP-2: macrophage inflammatory protein-2; PCR: polymerase chain reaction; RT: reverse transcriptase; 
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Introduction
Hyaluronan (HA), an important component of the extracellular
matrix, is composed of repeating disaccharide units containing
alternating D-glucuronic acid and N-acetyl glucosamine. HA
has been shown to produce distinct biological effects depend-
ing on the molecular weight. HA is synthesized by hyaluronan
synthase (HAS) that is located in the cell membrane, and is
secreted into the interstitial space [1]. In mammalian cell cul-
ture, HAS 1 and HAS 2 produce high-molecular-weight
hyaluronan (HMW HA), whereas HAS 3 produces low-molec-
ular-weight hyaluronan (LMW HA) [2,3].
HA has been identified as an important modulator in many
physiological and pathological processes. Under physiologi-
cal conditions, HA exists predominantly in the HMW HA form
(>500 kDa), and maintains the structural integrity of the extra-
cellular matrix in the lungs. In disease conditions during inflam-
mation, LMW HA (<500 kDa) is produced either by
depolymerization of HMW HA via oxygen radicals and enzy-
matic degradation by hyaluronidase, β-glucuronidase, and
hexosaminidase or by de novo synthesis through HAS 3 [4].
LMW HA can function as an intracellular signaling molecule in
inflammation and has been found to be proinflammatory [5,6].
We have found that LMW HA from stretched lung enhances
IL-8 expression, and that LMW HA production by HAS 3 medi-
ated ventilator-induced lung injury [7,8]. On the contrary,
HMW HA can block inflammation. Transgenic HAS 2 mice
that overexpress HMW HA have been found to be protected
from bleomycin-induced lung injury [9]. We hypothesized that
systemic administration of HMW HA would decrease sepsis-
induced lung injury with mechanical ventilation by inhibiting
cytokine production and lung inflammation.
Materials and methods
Animals
The present study was approved by the Massachusetts Gen-
eral Hospital Subcommittee on Research Animal Care.
Sprague–Dawley viral-free rats, all in the growing phase,
weighing between 185 and 225 g, were obtained from
Charles River Laboratories (Wilmington, MA, USA).
Ventilator protocol
The animals were anesthetized by intraperitoneal ketamine (90
mg/kg) (Abbott Laboratories, Chicago, IL, USA) and xylazine
(10 mg/kg; Burns Veterinary Supply Inc., Rockville Centre, NY,
USA) while breathing room air. Throughout the experiment, the
animals were placed in a supine position on a heating blanket
and the body temperature was monitored with a rectal probe.
PE 240 tubing (outer diameter, 2.42 mm; internal diameter,
1.67 mm; Becton Dickson Infusion Therapy System Inc.,
Sandy, UT, USA) was inserted into the trachea and connected
to a Harvard apparatus ventilator (model 55-7058; Harvard
Apparatus, Holliston, MA, USA). The rats were then ventilated
with a tidal volume of 7 ml/kg with a rate of 85 to 100 breaths
per minute.
The end-tidal carbon dioxide pressure was monitored intermit-
tently by a microcapnograph (Columbus Instruments, Colum-
bus, OH, USA), and was maintained between 35 and 45
mmHg by adjusting the ventilator respiratory rate. The volume
was increased by 5 ml/min to correct the air loss from the sam-
ple flow adaptor during monitoring of the end-tidal carbon
dioxide. The peak inspiratory airway pressure was measured
every 30 minutes with a pressure transducer amplifier (Gould
Instrument System, Valley View, OH, USA) connected to the
tubing at the proximal end of the tracheostomy.
The mean arterial pressure was measured every 30 minutes
during mechanical ventilation using the same pressure trans-
ducer amplifier connected to PE 10 tubing (outer diameter,
0.61 mm; inner diameter, 0.28 mm; Becton Dickson Infusion
Therapy System Inc., Sandy, Utah, USA) ending in the com-
mon carotid artery. During the period of ventilator use, intra-
peritoneal ketamine 0.05 mg/g and xylazine 0.005 mg/g were
administered every 30 minutes, and 0.9% NaCl was infused,
as needed, to maintain systolic blood pressure >90 mmHg.
Harvesting of lung and bronchoalveolar lavage (BAL) was per-
formed after 4 hours of mechanical ventilation.
Model of lipopolysaccharide-induced lung injury with 
mechanical ventilation and pretreatment with 
hyaluronan
Sprague–Dawley rats were randomly divided into four groups:
nonventilated control rats; mechanically ventilated rats with
lipopolysaccharide (LPS) infusion as a model of sepsis;
mechanical ventilation plus LPS infusion with HMW HA
(1,600 kDa) pretreatment; and mechanical ventilation plus
LPS infusion with LMW HA (35 kDa) pretreatment. Rats were
mechanically ventilated with a low tidal volume (7 ml/kg) (n =
5 or 6 rats/group) for 4 hours. Rats received 3 ml of 0.35% of
1,600 kDa or 35 kDa (Genzyme Corp., Cambridge, MA, USA)
pretreatment via the intraperitoneal route 18 hours prior to the
beginning of study.
All HA preparations were sterile and were protein free and
LPS free, to avoid known confounding effects of HA [10]. The
size and amount of HA was chosen based on previous work
that found HMW HA (>780 kDa) given intraperitoneally 18
hours before injection of concavalin protected against concav-
alin-induced liver toxicity. A dose response was found in this
model, and 0.35% HMW HA was most effective [11]. We
have shown that 1,600 kDa HA is the predominant size in nor-
mal rat lung [7]. Based on these findings, we used 0.35% of
1,600 kDa given intraperitoneally 18 hours prior to LPS infu-
sion.
Rats received either 1 mg/kg Salmonella typhosa LPS (Lot
81H4018; Sigma Chemical Co., St Louis, MO, USA) or anAvailable online http://ccforum.com/content/12/4/R102
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equivalent volume of normal saline as control via the carotid
artery. We have previously found arterial injection of LPS with
mechanical ventilation to cause acute lung injury within 4
hours of injection. After 1 hour of spontaneous respiration to
allow for development of a septic response, ventilation was
begun. We used an established rodent model of mechanical
ventilation as previously described [12-14]. Rats were sacri-
ficed with an overdose of pentobarbital after 4 hours of venti-
lation. The left lung was lavaged with normal saline for
measurement of cell counts and cytokines, macrophage
inflammatory protein-2 (MIP-2) and TNFα. The right lung was
flash frozen for the myeloperoxidase assay, for extraction of
RNA for the measurement of HA synthase, and for determining
the gene expression of cytokines, MIP-2 and TNFα. Separate
groups of animals were used for determination of lung pathol-
ogy.
Model of lipopolysaccharide-induced lung injury with 
mechanical ventilation and therapeutic treatment with 
hyaluronan
Rats were ventilated in the same manner as described for the
pretreatment with HA model. The 0.35% concentration of
1,600 kDa HA was too viscous for intravenous injection. For
the studies post acute lung injury treatment, we performed
dose–response studies with 0.025%, 0.05% and 0.1% of
1,600 kDa HA starting at the time of initiation of ventilation.
Intravenous infusion of 0.1% sodium carboxymethyl cellulose
(CMC) – a positive charged carbohydrate prepared from car-
boxymethylation of cellulose with a molecular weight of 1 ×
105 to 7.5 × 105 – was used as a control condition for charge
at 500 μl/hour. The infusion was continued throughout the
experiment.
Bronchoalveolar lavage
The lungs were removed en bloc and tubing was inserted into
the trachea and secured. The right lung was clamped at the
bronchus to prevent the lavage fluid from entering the right
lung. The left lung was lavaged with 2 ml of 0.9% normal saline
three times. One millilitre of the pooled effluents was used for
cytospin and subsequent cell differentials, and 100 μl was
used for the total cell counts. The remaining effluents were
centrifuged at 3,000 rpm for 10 minutes, after which the
supernatants were frozen at -80°C for further measurement of
cytokines.
Bronchoalveolar lavage cell counts
Neutrophil counts in BAL fluid were used to measure migration
of neutrophils into alveoli and airways [15]. Total cell counts in
BAL were performed using a hemocytometer. To measure cell
differentials, the cells in the lavage fluid were fixed on glass
slides with cytospin and were then stained with a hematologic
stain kit (Fisher Diagnostics, Middletown, VA, USA).
Myeloperoxidase assay
Myeloperoxidase activity in lung parenchyma was used as a
marker of total lung neutrophil sequestration, including neu-
trophils marginalized in the vasculature, and in the interstitium
and alveoli [13,15,16]. Samples of the right lower lobe were
obtained within a few minutes of death and were stored at -
80°C. The right lower lobe was thawed on ice, weighed, and
homogenized in 5 ml phosphate buffer (20 mM, pH 7.4). One
milliliter of the homogenate was centrifuged at 10,000 × g for
10 minutes at 4°C. The resulting pellet was resuspended in
1.0 ml phosphate buffer (50 mM, pH 6.0) containing 0.5%
hexadecyltrimethylammonium bromide (Sigma Chemical Co.).
The suspension was subjected to three cycles of freezing (on
dry ice) and thawing (at room temperature), after which it was
sonicated for 40 seconds and centrifuged again at 10,000 ×
g for 5 minutes at 4°C.
The supernatant was assayed for myeloperoxidase activity by
measurement of hydrogen peroxide-dependent oxidation of
3,3',5,5'-tetramethylbenzidine (Sigma Chemical Co.). In its oxi-
dized form, 3,3',5,5'-tetramethylbenzidine was measured by
spectrophotometer at 650 nm. The reaction mixture for analy-
sis consisted of 25 μl tissue samples, 25 μl 3,3',5,5'-tetrame-
thylbenzidine (final concentration, 0.16 mM) dissolved in
dimethylsulfoxide, and 200 μl hydrogen peroxide (final con-
centration, 0.30 mM) dissolved in phosphate buffer (0.08 M,
pH 5.4) prior to adding to the mixture. The reaction mixture
was incubated for 3 minutes at 37°C and the reaction stopped
by adding 1 ml sodium acetate (0.2 M, pH 3.0), after which
absorbance at 650 nm was measured. The absorbance fol-
lowed a linear relationship with the myeloperoxidase concen-
tration, which in turn is an enzyme marker for
leukosequestration. The absorbance (A650) was reported as
units (optical density) per gram of wet lung weight.
Measurement of MIP-2 and TNFα in lavage fluid
Rat MIP-2 and TNFα were measured in BAL fluid using a com-
mercially available ELISA kit containing antibodies that were
cross-reactive with rats and mouse MIP-2 (BioSource Interna-
tional, Inc., Camarillo, CA, USA). Each sample was run in dupli-
cate according to the protocol provided by the manufacturer.
Isolation of RNA and measurement of mRNA expression 
by RT-PCR
For isolation of total RNA, the lungs were homogenized in 1.5
ml Trizol reagent (Invitrogen Life Technologies, Carlsbad, CA,
USA) and were isolated according to the manufacturer's pro-
tocol. Total RNA (1 μg) was reversely transcribed into cDNA
using a Gene Amp PCR system 9600 (PerkinElmer Life Sci-
ences, Boston, MA, USA), as previously described [17].
The following primers of MIP-2 were used: PCR forward
primer, 5'-TCC TCA ATG CTG TAC TGG TCC-3' and reverse
primer, 5'-ATG TTC TTC CTT TCC AGG TC-3'; TNFα forward
primer, 5'-CAT GAT CCG AGA TGT GGA ACT-3' andCritical Care    Vol 12 No 4    Liu et al.
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reverse primer, 5'-TCA CAG AGC AAT GAC TCC AAA G-3';
and GAPDH (internal control) forward primer, 5'-AAT GCA
TCC TGC ACC ACC AA-3' and reverse primer, 5'-GTA GCC
ATA TTC ATT GTC ATA-3' (Sigma Chemical Co.).
The following cycling parameters were used: MIP-2, denatura-
tion at 94°C for 5 minutes followed by 35 cycles of 94°C for
30 seconds, annealing at 50°C for 45 seconds, and extension
at 72°C for 30 seconds, with a terminal extension at 72°C for
7 minutes; and for TNFα, denaturation at 94°C for 5 minutes
followed by 40 cycles of 94°C for 30 seconds, annealing at
58°C for 45 seconds, and extension at 72°C for 1 minute, with
a terminal extension at 72°C for 7 minutes.
Results were quantified using densitometry. The GAPDH and
cytokine signal densitometry was measured for each group.
The cytokine signal was normalized to GAPDH expression and
expressed as a ratio to control. A minimum of three mRNA
samples were analyzed for each group.
Pathology
After 4 hours of mechanical ventilation, the rats were sacri-
ficed and the lung and trachea were removed. The left lung
was infused at a pressure of 30 cmH2O with 10% buffered
formalin, embedded in paraffin, sectioned at 4 μm thickness,
and stained with hematoxylin and eosin. Ten randomly chosen
fields in the parenchyma (without large airways) from the indi-
vidual three lungs from each group were examined. Each of the
pathological changes was scored on a scale of 0 to 3: 0 =
alveolar filling, collapse or atelectasis (10×); 1 = inflammatory
cell infiltration in the air space or vessel wall (20×); 2 =
perivascular clubbing or swelling (10×); and 3 = alveolar hem-
orrhage or congestion (10×). The 10 randomly chosen fields
at low power (10×) covered over 80% of the left lung.
Because the injury was patchy, this technique gave an over-
view of the whole left lung. A higher power (20×) was needed
to accurately identify inflammatory cell infiltration. The overall
score was the sum of the average score for each category.
Two subspecialists who were blinded to the treatment groups
reviewed the degree of injury of each slides.
Statistical methods
Analysis was performed using Statview 4.5 (SAS Institute Inc.,
Cary, NC, USA). All data are expressed as the mean ± stand-
ard error of mean. Analysis of variance for comparison of the
different groups was used with significance set at P < 0.05. A
significant analysis of variance was followed by a Fisher test
for multiple comparisons between groups, significance set at
P < 0.05.
Results
Systolic pressure, heart rate and airway pressure in 
ventilated rats with hyaluronan pretreatment
For animals in the experiments involving HA pretreatment, the
systolic pressure was maintained with infusion of saline as
needed to maintain systolic blood pressure >70 mmHg to min-
imize the confounding effects of hypotension. The amount of
saline infused did not differ among groups. The peak airway
pressures for all animals were between 8 and 12 mmHg. The
systolic blood pressure did not differ among groups. The heart
rate was increased in animals exposed to LPS but was not sig-
nificantly different between treatment groups (Table 1).
Pretreatment with HMW HA (1,600 kDa) completely 
blocked both lung neutrophil and monocyte infiltration 
induced by mechanical ventilation
Rats receiving LPS had increased BAL neutrophils as com-
pared with rats without LPS treatment. Pretreatment with
HMW HA (1,600 kDa) decreased BAL neutrophils and the
total lung neutrophil infiltrate with LPS. The results were similar
with the use of 35 kDa HA (Figure 1). Lung neutrophil infiltra-
tion was confirmed with the myeloperoxidase assay (Figure 1).
Only 1,600 kDa HA, and not 35 kDa HAcompletely blocked
the increase in BAL monocytes. With LPS, 35 kDa HA only
partially blocked BAL monocyte infiltration (Figure 1).
Pretreatment with HMW HA (1,600 kDa) reduced the 
pathologic evidence of lung injury induced by 
lipopolysaccharide lung injury
Rats with LPS had poor alveolar distention and collapse, had
intense inflammatory cell infiltration in the interstitium, had
thickened perivascular clubbing and had alveolar hemorrhage
Table 1
Hemodynamics in the pretreatment model
Systolic blood pressure Heart rate
Group Baseline 4 hours Baseline 4 hours
Control 98 ± 7 85 ± 7 360 ± 7 327 ± 10
Lipopolysaccharide alone 100 ± 7 79 ± 5 436 ± 11 386 ± 11*
Lipopolysaccharide + 1,600 kDa hyaluronan 112 ± 7 96 ± 9 405 ± 64 412 ± 67*
Lipopolysaccharide + 35 kDa hyaluronan 100 ± 8 79 ± 7 369 ± 66 382 ± 65*
There were no statistical differences between groups for systolic blood pressure. In the lipopolysaccharide-exposed groups the heart rate was 
statistically higher, but there were no statistical differences between treatment groups. *P < 0.05 versus control.Available online http://ccforum.com/content/12/4/R102
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on pathology slides (Figure 2). The lung injury score of the rats
receiving LPS was significantly greater compared with rats
without LPS (Figure 3). We found that rats with LPS receiving
1,600 kDa HA pretreatment, but not 35 kDa HA pretreatment,
had less evidence of lung injury on pathology and had signifi-
cantly decreased lung injury scores (Figures 2 and 3). The inhi-
bition of lung injury by 1,600 kDa HA and not 35 kDa HA
correlated with 1,600 kDa HA inhibition of IL-1β.
Pretreatment with both 1,600 kDa and 35 kDa 
hyaluronan inhibited lipopolysaccharide-induced MIP-2 
and TNFα mRNA and protein production with mechanical 
ventilation
In a comparisonn between rats with and without LPS at the
same tidal volume, rats with LPS showed increased MIP-2 and
TNFα mRNA and protein levels compared with rats without
LPS. Rats receiving either 1,600 kDa HA or 35 kDa HA pre-
treatment showed less MIP-2 and TNFα production at the
mRNA and protein level compared with rats with sepsis (Fig-
ures 4 and 5).
Systolic blood pressure and heart rate in rats treated 
with HMW HA (1,600 kDa) 1 hour post lipopolysaccharide 
infusion
To further investigate the use of HMW HA infusion as a treat-
ment for sepsis-induced lung injury, HMW HA (0.025%, 0.5%
and 0.1%) was infused at 0.5 ml/hour starting at the time of
ventilation. For these experiments, the maximum dose of LPS
(3 mg/kg) that allowed survival of the animals was used. Saline
was infused as needed to maintain a systolic pressure of about
70 mmHg to eliminate the confounding effects of hypotension.
The systolic blood pressure was not significantly different
between groups.
The heart rate was significantly higher in animals exposed to
LPS, there were no significant differences between HMW HA-
treated groups, and animals treated with CMC had a higher
heart rate than those exposed to 0.1% HMW HA and than
control animals (Table 2). All doses of HA and CMC increased
the arterial oxygen pressure levels significantly (P  < 0.05)
above LPS-exposed animals (LPS, 51 ± 10 mmHg; LPS +
0.025% HA, 84 ± 7 mmHg; LPS + 0.05% HA, 67 ± 3 mmHg;
LPS + 0.1% HA and LPS + 0.1% CMC, 75 ± 7 mmHg).
Treatment with HMW HA (1,600 kDa) 1 hour post 
lipopolysaccharide infusion blocked both lung 
neutrophil infiltration and acute lung injury in a dose-
dependent manner
HMW HA inhibited neutrophil infiltration (Figure 6), MIP-2
mRNA expression (data not shown), and acute lung injury
scores (Figure 7) in a dose-dependent manner. To evaluate
whether this effect was secondary to the positive charge of HA
or to the anti-inflammatory properties of HA, 0.1% CMC was
infused at 0.5 ml/hour. CMC at an equal concentration to
HMW HA (0.1%) partially blocked lung neutrophil infiltration
(Figure 6) and lung injury (Figure 7), but not to the same extent
as HMW HA – suggesting that the positive charge of HMW
HA was at least partially responsible for the therapeutic
effects.
Figure 1
Only high-molecular-weight hyaluronan (1,600 kDa) completely  blocked both lung neutrophil and monocyte infiltration Only high-molecular-weight hyaluronan (1,600 kDa) completely 
blocked both lung neutrophil and monocyte infiltration. Animals were 
pretreated with either 1,600 kDa or 35 kDa hyaluronan 18 hours prior 
to ventilation. Lipopolysaccharide (LPS) (1 mg/kg) was given by arterial 
injection 1 hour prior to the start of ventilation. After 4 hours of ventila-
tion, animals were sacrificed and the left lung was lavaged. (a) Neu-
trophils × 10,000/ml bronchoalveolar lavage fluid (BAL). (b) 
Monocytes × 10,000/ml BAL. (c) Myeloperoxidase assay optical den-
sity (MPO OD)/mg lung tissue. *P < 0.01 versus control, #P < 0.01 
versus with LPS. Non-vent, nonventilated.Critical Care    Vol 12 No 4    Liu et al.
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Post-treatment with intraperitoneal HMW HA failed to protect
against inhalation acute lung injury, and therefore was not
used in the present study (data not shown)
Discussion
In the present study we investigated whether administration of
exogenous HMW HA could be used as a therapy for sepsis-
induced acute lung injury with mechanical ventilation. We
demonstrated that pretreatment with HMW HA (1,600 kDa)
inhibited inflammatory cell infiltration, cytokine production, and
lung injury with mechanical ventilation. LMW HA (35 kDa)
inhibited lung neutrophil infiltration and cytokine production,
but did not inhibit lung injury or lung monocyte infiltration.
HMW HA used in a therapeutic manner 1 hour after LPS infu-
sion inhibited LPS-induced lung inflammation and lung injury in
a dose-dependent manner.
HMW HA is an effective treatment in a variety of disease con-
ditions. HMW HA has been shown to be a beneficial treatment
for osteoarthritis. HMW HA can downregulate proinflamma-
tory cytokines including IL-8, TNFα, and inducible nitric oxide
synthase in fibroblast-like synoviocytes [18]. HMW HA pre-
vented acute liver injury by reducing plasma MIP-2, TNFα, and
IFNγ in a T-cell-mediated liver injury mouse model [11]. HMW
HA has been shown to be protective in animal models of
emphysema, can decrease the number of acute infections in
chronic bronchitis in humans, can block group A streptococ-
cus colonization in mice, can block pancreatic elastase-
induced bronchoconstriction and neutrophil elastase-induced
airway responses in sheep, can decrease peritoneal permea-
bility secondary to infection in rats, and can reduce exercise-
induced airway hyperreactivity in humans [19-23]. Beneficial
effects in sepsis, however, have not been previously demon-
strated.
Our findings are consistent with previous observations that
mice overexpressing HMW HA are protected from bleomycin-
induced lung injury [9]. Both HAS 1 and HAS 2 produced
HMW HA. HASs are located on the cell surface and secrete
the chains of HA into the extracellular matrix [1]. We have
found in the normal lung that HA is of the HMW HA form; how-
ever, in high-tidal-volume-induced lung injury in rats we found
both HMW HA and LMW HA.
To establish whether HMW HA could potentially have benefi-
cial effects in the treatment of sepsis we initially used pretreat-
ment with an intraperitoneal injection of 35% HMW HA prior
to LPS injection. This concentration, given intraperitoneally 18
hours before liver injury, has been shown to be absorbed into
the systemic circulation and to prevent concavalin-induced
liver injury [11]. We then explored the use of HMW HA as a
treatment for sepsis-induced lung injury. We had in previous
studies found that HMW HA given intraperitoneally after
smoke inhalation failed to protect lung injury (data not shown),
probably related to delayed absorption, and 35% HMW HA
Figure 2
Only high-molecular-weight hyaluronan (1,600 kDa) decreased lung injury on pathology Only high-molecular-weight hyaluronan (1,600 kDa) decreased lung injury on pathology. Animals were pretreated with either 1,600 kDa or 35 kDa 
hyaluronan 18 hours prior to ventilation. Lipopolysaccharide (LPS) (1 mg/kg) was given by arterial injection 1 hour prior to the start of ventilation. 
After 4 hours of ventilation, animals were sacrificed and the left lung was fixed with formaldehyde, sliced and stained with hematoxylin and eosin. 
LPS caused edema and inflammatory cell infiltration, which was decreased with high-molecular-weight hyaluronan pretreatment. Non-vent, nonventi-
lated.
Figure 3
Only high-molecular-weight hyaluronan (1,600 kDa) significantly  decreased the lung injury score Only high-molecular-weight hyaluronan (1,600 kDa) significantly 
decreased the lung injury score. Animals were pretreated with either 
1,600 kDa or 35 kDa hyaluronan 18 hours prior to ventilation. Lipopoly-
saccharide (LPS 1 mg/kg) was given by arterial injection 1 hour prior to 
the start of ventilation. After 4 hours of ventilation, animals were sacri-
ficed and the left lung was fixed with formaldehyde, sliced and stained 
with hematoxylin and eosin. Lung injury, measured by the lung injury 
score as described in Materials and methods, showed substantial pro-
tection by 1,600 kDa hyaluronan but not 35 kDa hyaluronan. *P < 0.01 
versus control, #P < 0.01 versus LPS. Non-vent, nonventilated.Available online http://ccforum.com/content/12/4/R102
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was too viscous for intravenous injection. We therefore used
continuous infusion of 0.025%, 0.05% and 0.1% HMW HA,
concentrations that allowed intravenous infusion, starting 1
hour after injection of LPS.
We used intra-arterial LPS rather than the more conventional
intravenous route of injection. We designed our model to pro-
duce lung injury over a 4-hour period that did not result in
death but in a lung injury that was increased by high-tidal-vol-
ume ventilation over this period. We studied both venous and
arterial injection. With arterial injection we found that there
was increased neutrophil infiltration with arterial injection (61
× 103 ± 10 cells/ml BAL fluid) than with venous injection (23
× 103 ± 1 cells/ml BAL fluid, P  < 0.05). Based on this
response we chose the intra-arterial route. Intra-arterial injec-
tion has been used in other models of sepsis [24,25].
The difference in effects on acute lung injury scores between
HMW HA and LMW HA may have been related to the different
effects of the two molecular weights. HMW HA may block the
effects of LMW HA produced in lung injury. The breakdown of
HMW HA causes HA fragments to increase quickly and mark-
edly in response to endotoxin [26], and elevated levels of
plasma HA fragments have been detected in patients with
Figure 4
Hyaluronan (1,600 kDa and 35 kDa) inhibited cytokine mRNA expres- sion Hyaluronan (1,600 kDa and 35 kDa) inhibited cytokine mRNA expres-
sion. Animals were pretreated with either 1,600 kDa or 35 kDa hyaluro-
nan 18 hours prior to ventilation. Lipopolysaccharide (LPS) (1 mg/kg) 
was given by arterial injection 1 hour prior to the start of ventilation. 
After 4 hours of ventilation, animals were sacrificed and the right upper 
lobe was flash frozen for extraction of RNA. Macrophage inflammatory 
protein-2 (MIP-2) and TNFα mRNA expression was decreased with 
high-molecular-weight hyaluronan or low-molecular-weight hyaluronan. 
(a) RT-PCR. (b) Quantitation of mRNA expression for MIP-2. (c) Quan-
titation of mRNA expression for TNFα. C, Control; L, LPS. *P < 0.05 
versus control, #P < 0.05 versus LPS.
Figure 5
Pretreatment with hyaluronan (1,600 kDa and 35 kDa) inhibited  cytokine protein expression Pretreatment with hyaluronan (1,600 kDa and 35 kDa) inhibited 
cytokine protein expression. Animals were pretreated with either 1,600 
kDa or 35 kDa hyaluronan 18 hours prior to ventilation. Lipopolysac-
charide (LPS) (1 mg/kg) was given by arterial injection 1 hour prior to 
the start of ventilation. After 4 hours of ventilation, animals were sacri-
ficed and the left lung was lavaged. Cytokine protein expression in 
bronchoalveolar lavage fluid (BAL) when measured by ELISA. Macro-
phage inflammatory protein-2 (MIP-2) and TNFα protein expression 
was decreased with high-molecular-weight hyaluronan or low-molecu-
lar-weight hyaluronan. (a) MIP-2. (b) TNFα. *P < 0.05 versus control, 
#P < 0.05 versus LPS. Non-vent, nonventilated.Critical Care    Vol 12 No 4    Liu et al.
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septicemia [27]. LMW HA (200 kDa) isolated from the serum
of patients with acute lung injury stimulated cytokine produc-
tion in macrophages [9]. LMW HA mediates bleomycin-
induced lung injury [9,28-31].
In previous studies, we demonstrated that de novo synthesis
of LMW HA by HAS 3 was induced in lung fibroblasts
exposed to cyclic stretch via tyrosine kinase signaling path-
ways [7]. In vivo, very-high-tidal-volume ventilation (30 ml/kg)
induced LMW HA production, was dependent on HAS 3, and
resulted in increased neutrophil infiltration in the lungs of mice
[8]. Alternatively, the beneficial effects of HMW HA inhibition
on inflammation may have been secondary to an increase in
the ratio of HMW HA to LMW HA, thereby maintaining the
level of HMW HA in the extracellular matrix and maintaining the
integrity of the extracellular matrix [4,29].
HA receptors include CD44, RHAMM, Toll-like receptor 2 and
Toll-like receptor 4 [9,32-34]. LMW HA induces cytokine pro-
duction by binding to HA cell surface receptors. LMW HA
(200 kDa) isolated from the serum of patients with acute lung
injury stimulated cytokine production by binding to Toll-like
receptor 2 and Toll-like receptor 4. LMW HA binding to Toll-
Table 2
Hemodynamics in the treatment model
Systolic blood pressure Heart rate
Group Baseline 4 hours Baseline 4 hours
Control 125 ± 6 88 ± 6 425 ± 25 327 ± 9
LPS alone 98 ± 8 70 ± 5 465 ± 11 438 ± 28*
LPS + 0.025% of 1,600 kDa HMW HA 125 ± 5 72 ± 8 442 ± 21 448 ± 9*
LPS + 0.5% of 1,600 kDa HMW HA 112 ± 9 86 ± 6 475 ± 17 445 ± 10*
LPS + 0.1% of 1,600 kDa HMW HA 97 ± 16 87 ± 6 495 ± 18 401 ± 23*
LPS + 0.1% sodium carboxymethyl cellulose 97 ± 8 85 ± 7 464 ± 18 474 ± 30* †
There were no statistical differences between groups for systolic blood pressure. In the lipopolysaccharide (LPS)-exposed groups the heart rate 
was statistically higher, but there were no statistical differences between the high-molecular-weight hyaluronan (HMW HA) treatment groups. LPS 
+ 0.1% sodium carboxymethyl cellulose was statistically higher than LPS + 0.1% HMW HA. *P < 0.01 versus control. †P < 0.01 versus LPS + 
0.1% HMW HA.
Figure 6
High-molecular-weight hyaluronan (1,600 kDa) given after lipopolysac- charide infusion blocked neutrophil infiltration in a dose-dependent  manner High-molecular-weight hyaluronan (1,600 kDa) given after lipopolysac-
charide infusion blocked neutrophil infiltration in a dose-dependent 
manner. Animals were infused with 0.025%, 0.05%, or 0.1% high-
molecular-weight hyaluronan (HMW HA) or 0.1% sodium carboxyme-
thyl cellulose (CMC) at 500 μl/hour starting 1 hour after lipopolysac-
charide (LPS) (3 mg/kg) infusion. Intravenous HMW HA given post 
LPS infusion showed a dose-dependent decrease in neutrophil infiltra-
tion, which was only partially explained by charge – as evidenced by 
significantly less inhibition with 0.1% CMC, a positively charged carbo-
hydrate of similar molecular weight, as compared with 0.1% HMW HA. 
*P < 0.05 versus LPS, #P < 0.05 versus LPS + 0.1% HMW HA. BAL, 
bronchoalveolar lavage.
Figure 7
High-molecular-weight hyaluronan (1,600 kDa) given after lipopolysac- charide infusion blocked lung injury in a dose-dependent manner High-molecular-weight hyaluronan (1,600 kDa) given after lipopolysac-
charide infusion blocked lung injury in a dose-dependent manner. Ani-
mals were infused with 0.025%, 0.05%, or 0.1% high-molecular-
weight hyaluronan (HMW HA) or 0.1% sodium carboxymethyl cellulose 
(CMC) at 500 ml/hour starting 1 hour after lipopolysaccharide (LPS) 
infusion. *P < 0.05 versus LPS, #P < 0.05 versus LPS + 0.1% HMW 
HA.Available online http://ccforum.com/content/12/4/R102
Page 9 of 11
(page number not for citation purposes)
like receptor 2 and Toll-like receptor 4 initiates mRNA expres-
sion by activation of the JNK pathways and through MyD88
activation [9,33,34]. HMW HA has been shown to block the
action of LMW HA by competing LMW HA binding to its
receptors [35]. The beneficial effects of HMW HA in this
model of sepsis may have been secondary to HMW HA block-
ing the binding of LPS or LMW HA to Toll-like receptors,
which mediate inflammation.
Surprisingly, infusion of LMW HA – at the size (35 kDa) and
concentration (up to 1%) used in the present study – did not
cause increased inflammation, and actually inhibited lung
inflammation. LMW HA has been found to be proinflammatory
by many authors, but not in all studies. Other authors have
found that it is the protein and DNA contamination found in the
LMW HA that is proinflammatory, and not the LMW HA itself
[10,36]. One explanation of the lack of proinflammatory effects
of the HA used in this study is the purity of the compound. The
HA used in the present study has <0.1% protein and <0.1
absorbance units of neucleotides. We cannot rule out longer
exposures or higher concentrations of LMW HA or other sizes
of LMW HA causing inflammation. Since the 35 kDa LMW HA
failed to prevent acute lung injury on pathology in our pretreat-
ment studies, we did not use LMW HA in the postinjury stud-
ies.
Both HMW HA and LMW HA inhibited MIP-2 production in
the BAL and inhibited infiltration of neutrophils and monocytes
into the lung. The inhibition of MIP-2 most probably accounts
for this effect. It has been previously shown that a gradient of
chemokines between the alveoli and the circulation is needed
to induce migration into the alveolar space [15]. We have pre-
viously shown that neutralization of MIP-2 in the airways pre-
vents lung inflammatory cell infiltration in ventilator-induced
lung inflammation [13].
Alternatively the beneficial effects were not secondary HMW
HA inhibition of LMW HA, but secondary to an increase in the
ratio of HMW HA to LMW HA – thereby maintaining the level
of HMW HA in the extracellular matrix and maintaining the
integrity of the extracellular matrix [4], and preventing the influx
of inflammatory cytokines into the alveoli. This maintenance of
the extracellular matrix may be an important mechanism in the
prevention of acute lung injury by HMW HA.
Infusion of CMC, a carbohydrate with a positive charge similar
size to the HMW HA, was used to control for the effects of
charge. CMC blocked inflammation and lung injury – but not
to the same extent as HMW HA. Since LMW HA and CMC
partially blocked lung inflammation, the positive charge of HA
may play a role in preventing lung injury by binding negatively
charged inflammatory proteins.
One limitation of our study comparing LMW HA and HMW HA
is the difference in molarity between the two infusions. We
were unable to match molarity with the two infusions, since the
high concentration of LMW HA that would be necessary to
match the molarity between the solutions was not soluble. We
cannot rule out that the beneficial effects of HMW HA may be
due to the higher molarity of the solution being a better method
of fluid resuscitation. We used additional saline infusions,
however, to maintain the systolic blood pressure above 70
mmHg to eliminate hypotension as a confounding factor. The
systolic blood pressure did not differ between groups.
An important part of our model is the use of mechanical venti-
lation with LPS infusion. The management of acute respiratory
failure requires the use of positive-pressure mechanical venti-
lation to provide adequate ventilation and oxygenation. But
mechanical ventilation with a high tidal volume leads to venti-
lator-induced lung injury by alveolar overdistention coupled
with repeated collapse and reopening during mechanical ven-
tilation, which initiates a cascade of proinflammatory
cytokines. Even mechanical ventilation with moderate tidal vol-
umes can augment the sepsis-induced lung injury by synergis-
tically increasing lung cytokines, and may play a pivotal role in
the development of acute lung injury in patients with sepsis
[37-40]. The augmentation of acute lung injury by high tidal
volumes has been termed ventilator-associated lung injury.
Conclusion
HMW HA attenuated both lung inflammation and the extent of
lung injury in a rat model of sepsis with mechanical ventilation,
whereas LMW HA only inhibited lung inflammation and not the
acute lung injury scores. These findings of the beneficial
effects of HA in sepsis-induced lung injury are intriguing and
warrant further investigation. Since LMW HA and CMC, a car-
bohydrate with a positive charge, also partially blocked lung
inflammation, the size of HA may not be the only factor involved
in the prevention of lung inflammation.
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